Pregled bibliografske jedinice broj: 1275692
The role of genetic testing in breast cancer patients undergoing neoadjuvant treatment
The role of genetic testing in breast cancer patients undergoing neoadjuvant treatment // Libri oncologici
Opatija, Hrvatska, 2020. str. 100-101 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 1275692 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The role of genetic testing in breast cancer
patients undergoing neoadjuvant treatment
Autori
Šabarić, Viktor ; Kanceljak, Kristina ; Lonjak, Nikolina ; Žigman, Tamara ; Rako, Ivana ; Gotovac Jerčić, Kristina ; Borovečki, Fran ; Silovski, Tajana ; Dedić Plavetić, Natalija
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Libri oncologici
/ - , 2020, 100-101
Skup
13. Hrvatski onkološki kongres
Mjesto i datum
Opatija, Hrvatska, 03.09.2020. - 06.09.2020
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Breast cancer, neoadjuvant therapy, genetic testing
Sažetak
Pathologic complete response (pCR) after neoadjuvant systemic treatment appears to be a valid surrogate for better overall survival in breast cancer patients. Together with standard clinicopathologic assessment novel molecular biomarkers and genetic mutations are being tested in order to look into the heterogeneity of breast cancer. Advances in molecular genetics have identified a number of genes associated with inherited susceptibility to breast and ovarian cancer (BRCA1/2, TP53, PALB2, CHECK2, ATM, LZTR1, MSH6, BRIP1, AIP). The aim of our study was to find pathogenic mutations before making a treatment plan for patients undergoing neoadjuvant treatment. On a small number of patients we found a significant number of pathogenic and likely pathogenic variants with high clinical relevance. Germline BRCA1 and BRCA2 mutations are frequently detected among patients with TNBC, a subgroup that can benefit most from a new therapeutic options. Small, pivotal trial has shown promising results of pathologic complete reponse with talazoparib monotherapy as a neoadjuant treatment in germline BRCA mutation carriers. In our small subset of patients with BRCA1 and BRCA2 mutations, all patients were subjected to radical mastectomy instead of breastconserving surgery, regardless of good response to neoadjuvant chemotherapy.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinika za tumore,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Tamara Žigman
(autor)
Ivana Rako
(autor)
Nikolina Lonjak
(autor)
Natalija Dedić-Plavetić
(autor)
Tajana Silovski
(autor)
Fran Borovečki
(autor)
Kristina Gotovac Jerčić
(autor)